Whitney Sims, PA
Medical · Florence, SCNPI 1073161634
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,290 and has fallen 52.7% since, to $611 in 2025.
Across 234 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$887
- Novartis$658
- Johnson & Johnson$462
- Pfizer$284
- E.r. Squibb & Sons, L.L.C.$262
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$234
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,452100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $887 |
| Novartis | 41 | $658 |
| Johnson & Johnson | 28 | $462 |
| Pfizer | 16 | $284 |
| E.r. Squibb & Sons, L.L.C. | 15 | $262 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $234 |
| Boehringer Ingelheim | 12 | $231 |
| Amgen | 13 | $203 |
| Merck | 9 | $149 |
| Boston Scientific | 7 | $145 |
| Esperion Therapeutics, Inc. | 9 | $141 |
| Novo Nordisk | 5 | $140 |
| Chiesi USA, Inc. | 6 | $97 |
| Lexicon Pharmaceuticals, Inc. | 4 | $91 |
| Lilly USA, LLC | 1 | $88 |
| Convatec Inc. | 1 | $69 |
| Inari Medical, Inc. | 2 | $57 |
| Corcept Therapeutics | 2 | $49 |
| Amarin Pharma, Inc. | 2 | $35 |
| Impulse Dynamics (USA) Inc. | 1 | $30 |
| Abiomed | 1 | $28 |
| Bayer | 1 | $27 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Vital Connect, Inc | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$106
How this compares
$4,452 in reported general payments places this provider in the 80th percentile of 384 medical providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 118 | $101,475 |
| JardianceEmpagliflozin | 48 | $57,026 |
| EntrestoSacubitril/Valsartan | 55 | $54,065 |
| XareltoRivaroxaban | 46 | $36,342 |
| FarxigaDapagliflozin Propanediol | 43 | $31,825 |
| Ranolazine ErRanolazine | 59 | $4,428 |
| Metoprolol Succinate | 164 | $2,404 |
| Dofetilide | 14 | $1,416 |
| Carvedilol | 154 | $1,410 |
| Nifedipine ErNifedipine | 58 | $1,298 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 83 | $1,019 |
| Atorvastatin Calcium | 62 | $948 |
| Valsartan | 56 | $941 |
| Amlodipine Besylate | 142 | $795 |
| Losartan Potassium | 101 | $769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $284 | $101,475118 claims |
| Boehringer IngelheimJardiance | $231 | $57,02648 claims |
| NovartisEntresto | $658 | $54,06555 claims |
| Johnson & JohnsonXarelto | $462 | $36,34246 claims |
| AstraZenecaFarxiga | $887 | $31,82543 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 384 medical providers in South Carolina.
Other medical in Florence
- Charlotte HannaFlorence$5K
- Christopher ThompsonSpartanburg$78K
- Laura BuchGreenville$73K
- Suzanne SmithWest Columbia$39K
- Stavros ChrysostomidesColumbia$39K
- Ethan CaseySpartanburg$24K
- Jessica HallColumbia$22K
- Mary MacdonaldCharleston$20K
- Cameron PappasGreenville$18K
- Leslie RumbautGrenville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.